Assertio (ASRT)

• Market cap: $66.2M
• 1 day: -2.69%
• 5 days: 4.70%
• 1 month: 5.98%
• 3 months: 11.45%
• 6 months: -14.36%
• Year to date: -18.72%
• 1 year: -60.06%
• 5 years: -78.80%
• 10 years: -99.43%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.

Employees: 30

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

479% more call options, than puts

Call options by funds: $1.05M | Put options by funds: $181K

2.66% less ownership

Funds ownership: 29.18% [Q4 2024] → 26.52% (-2.66%) [Q1 2025]

17% less funds holding

Funds holding: 82 [Q4 2024] → 68 (-14) [Q1 2025]

29% less capital invested

Capital invested by funds: $24.3M [Q4 2024] → $17.1M (-$7.14M) [Q1 2025]

50% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 28

82% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 17

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $3.50 407% upside
• Avg. target: $3.50 407% upside
• High target: $3.50 407% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Raghuram Selvaraju

407% upside $3.50

Buy Reiterated

19 May 2025